Weihong Zhang

Weihong Zhang currently serves as the Director of CMC at Baruch S. Blumberg Institute since March 2023. Prior to this role, Weihong Zhang held the position of Director of Chemical Development at Proteovant Therapeutics from February 2022 to January 2023. Weihong Zhang's background includes significant experience at Bristol Myers Squibb as a Senior Principal Scientist from October 2019 to February 2022 and a long tenure at Celgene, progressing from Research Scientist to Senior Principal Scientist from June 2001 to September 2019. Academic achievements include a Post-doctoral degree in Organic Synthesis from Yale University and a PhD in Organic Chemistry from Rutgers University–New Brunswick, along with a Bachelor of Science in Chemistry from Wuhan University.